B-SOFTLtd Valuation
Is 300451 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 300451 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 300451 (CN¥5.22) is trading above our estimate of fair value (CN¥0.09)
Significantly Below Fair Value: 300451 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 300451?
Key metric: As 300451 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 300451's PS Ratio? | |
|---|---|
| PS Ratio | 5x |
| Sales | CN¥1.63b |
| Market Cap | CN¥8.06b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.6x |
| Enterprise Value/EBITDA | 5242.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 300451's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 10.4x | ||
300288 Longmaster Information & Technology | 12.8x | n/a | CN¥5.3b |
300550 Heren HealthLtd | 8.8x | n/a | CN¥3.7b |
688246 Goodwill E-Health Info | 6.5x | 23.7% | CN¥4.1b |
301337 Yarward Electronics (Shandong) | 13.3x | n/a | CN¥3.4b |
300451 B-SOFTLtd | 5x | 17.1% | CN¥8.1b |
Price-To-Sales vs Peers: 300451 is good value based on its Price-To-Sales Ratio (5x) compared to the peer average (10.4x).
Price to Sales Ratio vs Industry
How does 300451's PS Ratio compare vs other companies in the Asian Healthcare Services Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 300451 is expensive based on its Price-To-Sales Ratio (5x) compared to the Asian Healthcare Services industry average (4.8x).
Price to Sales Ratio vs Fair Ratio
What is 300451's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5x |
| Fair PS Ratio | 2.8x |
Price-To-Sales vs Fair Ratio: 300451 is expensive based on its Price-To-Sales Ratio (5x) compared to the estimated Fair Price-To-Sales Ratio (2.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CN¥5.22 | CN¥5.74 +10.0% | 16.9% | CN¥6.82 | CN¥4.40 | n/a | 4 |
| Nov ’25 | CN¥5.09 | CN¥5.74 +12.8% | 16.9% | CN¥6.82 | CN¥4.40 | n/a | 4 |
| Oct ’25 | CN¥4.87 | CN¥4.74 -2.8% | 7.0% | CN¥5.25 | CN¥4.40 | n/a | 4 |
| Sep ’25 | CN¥3.33 | CN¥4.92 +47.8% | 13.0% | CN¥6.00 | CN¥4.40 | n/a | 4 |
| Aug ’25 | CN¥3.44 | CN¥5.88 +70.9% | 7.0% | CN¥6.50 | CN¥5.50 | n/a | 4 |
| Jul ’25 | CN¥3.44 | CN¥5.88 +70.9% | 7.0% | CN¥6.50 | CN¥5.50 | n/a | 4 |
| Jun ’25 | CN¥4.09 | CN¥5.88 +43.7% | 7.0% | CN¥6.50 | CN¥5.50 | n/a | 4 |
| May ’25 | CN¥4.27 | CN¥5.88 +37.6% | 7.0% | CN¥6.50 | CN¥5.50 | n/a | 4 |
| Apr ’25 | CN¥4.69 | CN¥9.63 +105.4% | 5.4% | CN¥10.00 | CN¥8.90 | n/a | 3 |
| Mar ’25 | CN¥4.85 | CN¥9.63 +98.6% | 5.4% | CN¥10.00 | CN¥8.90 | n/a | 3 |
| Feb ’25 | CN¥4.28 | CN¥9.63 +125.1% | 5.4% | CN¥10.00 | CN¥8.90 | n/a | 3 |
| Jan ’25 | CN¥6.55 | CN¥9.63 +47.1% | 5.4% | CN¥10.00 | CN¥8.90 | n/a | 3 |
| Dec ’24 | CN¥7.55 | CN¥10.76 +42.5% | 7.4% | CN¥11.83 | CN¥10.00 | n/a | 4 |
| Nov ’24 | CN¥7.18 | CN¥10.18 +41.8% | 10.3% | CN¥11.83 | CN¥8.90 | CN¥5.09 | 4 |
| Oct ’24 | CN¥6.74 | CN¥11.26 +67.1% | 7.0% | CN¥12.00 | CN¥10.00 | CN¥4.87 | 4 |
| Sep ’24 | CN¥6.50 | CN¥12.01 +84.8% | 5.3% | CN¥13.00 | CN¥11.22 | CN¥3.33 | 4 |
| Aug ’24 | CN¥7.30 | CN¥12.43 +70.3% | 4.2% | CN¥13.00 | CN¥11.83 | CN¥3.44 | 4 |
| Jul ’24 | CN¥8.38 | CN¥12.43 +48.4% | 4.2% | CN¥13.00 | CN¥11.83 | CN¥3.44 | 4 |
| Jun ’24 | CN¥8.83 | CN¥12.43 +40.8% | 4.2% | CN¥13.00 | CN¥11.83 | CN¥4.09 | 4 |
| May ’24 | CN¥8.60 | CN¥12.69 +47.6% | 3.2% | CN¥13.00 | CN¥12.00 | CN¥4.27 | 4 |
| Apr ’24 | CN¥10.98 | CN¥10.42 -5.1% | 17.4% | CN¥12.86 | CN¥8.50 | CN¥4.69 | 3 |
| Mar ’24 | CN¥9.60 | CN¥10.42 +8.5% | 17.4% | CN¥12.86 | CN¥8.50 | CN¥4.85 | 3 |
| Feb ’24 | CN¥9.11 | CN¥9.20 +1.0% | 7.6% | CN¥9.90 | CN¥8.50 | CN¥4.28 | 2 |
| Jan ’24 | CN¥7.91 | CN¥9.20 +16.3% | 7.6% | CN¥9.90 | CN¥8.50 | CN¥6.55 | 2 |
| Dec ’23 | CN¥8.46 | CN¥9.20 +8.7% | 7.6% | CN¥9.90 | CN¥8.50 | CN¥7.55 | 2 |
| Nov ’23 | CN¥8.16 | CN¥9.63 +18.1% | 8.7% | CN¥10.50 | CN¥8.50 | CN¥7.18 | 3 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
iRay Technology
CN¥16.0b
Develops, manufactures, and sells flat panel X-ray detectors for use in medical, dental, oncology, veterinary, security, and industrial imaging applications in China and internationally.
688301
CN¥111.99
7D
-0.8%
1Y
-28.0%
Shenzhen Lifotronic Technology
CN¥6.8b
Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.
688389
CN¥15.96
7D
-3.3%
1Y
-34.8%
Innovita Biological Technology
CN¥5.7b
Engages in the research and development, manufacturing, marketing, and sales of POCT rapid diagnostic products.
688253
CN¥41.76
7D
-5.2%
1Y
24.5%